Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two major healthcare stocks: Bristol Myers Squibb (BMY), a specialized biopharmaceutical company focused on oncology and immunology, and Johnson & Johnson (JNJ), a diversified healthcare giant with innovative medicine and medical device segments. While BMY trades at a significant valuation discount with a higher dividend yield (4.51%), JNJ is recommended as the better 2026 buy due to its stronger growth prospects, superior margins (28.5% vs 14.6%), robust free cash flow ($20B vs $12.8B), and more diversified revenue streams with 28 billion-dollar products. Both face patent cliff challenges and government price negotiation pressures.